The Europe Allergy Immunotherapy Market would witness market growth of 7.2% CAGR during the forecast period (2023-2030).
Allergy immunotherapy involves frequent injections that increase the amount to help the patient develop resistance. The patient's immune system becomes less vulnerable as the dosage gradually increases because more blocking antibodies are produced to fight the foreign chemicals that trigger allergies. Because allergic reactions often bring it on and are strongly related to other allergic disorders, asthma is a significant allergy component. As a result, the market is a subsegment of the overall market that is devoted to developing drugs for treating asthma and allergic disorders.
A major trend in the market is a shift toward more individualized and targeted treatment. Growing knowledge exists on the molecular processes that underlie allergic reactions. To satisfy each patient's unique needs, researchers and physicians are creating increasingly sophisticated, customized therapy. The development of biomarkers and diagnostic tools to assist in determining the underlying causes of allergies and directing treatment choices is also driven by this trend.
Most people who live in cities in Europe perform this in areas where the EU's regulations for air quality protection of human health are commonly surpassed. The UK government estimates that 1 to 2% of adults and 5 to 8% of youths in the country suffer from food allergies. Hypersensitivity to food cannot be cured. It necessitates ongoing management. A single action cannot make a consumer's risk disappear. Food allergies will increase because of these factors. Overall, the market is anticipated to expand in this region due to the rise in various allergens.
The Germany market dominated the Europe Allergy Immunotherapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $238.5 million by 2030. The UK market is estimated to grow at a CAGR of 6.2% during (2023 - 2030). Additionally, The France market would witness a CAGR of 8% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Treatment Type, the market is segmented into Subcutaneous Immunotherapy (SCIT), and Sublingual Immunotherapy (SLIT) (Tablets, and Drops). Based on Allergy Type, the market is segmented into Allergic Rhinitis, Allergic Asthma, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Allergy Immunotherapy Market is Projected to reach USD 2.9 Billion by 2030, at a CAGR of 8.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc. (Mylan N.V.), Merck KGaA , NIOX Group plc , DMS Imaging SA, Adamis Pharmaceuticals Corporation, Stallergenes Greer International AG (B-Flexion), Allergy Therapeutics plc , DBV Technologies S.A., HAL Allergy B.V. (Droege International Group AG.), LETI Pharma, S.L.U.
By Distribution Channel
By Treatment Type
By Allergy Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
